US4883666A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled drug delivery system for treatment of neural disorders
Assignee: Massachusetts Institute of Technology
•
Filing: 1987-04-29
•
Granted: 1989-11-28
•
Expires: 2007-04-29
Abstract
Abstract The present invention is a method and composition for treatment of ischemic, metabolic, congenital, or degenerative disorders of the central or peripheral nervous system. The composition is formed by encapsulation within an implantable biocompatible polymeric device of one or more compounds which have the effect or replacing or stimulating functions of the nervous system. A variety of biocompatible polymers including both biodegradable and non-degradable polymers can be used to form the implants. An essential feature of the composition is linear release, achieved through manipulation of the polymer composition and form. The selection of the shape, size, drug, polymer, and method for implantation are determined on an individual basis according to the disorder to be treated and the individual patient response. A plethora of neurally active substances can be used to treat or manipulate neurological disorders, including Parkinson's Disease, particularly the subset which is refractory or poorly responsive to existing therapies; Alzheimer's Disease; Huntington's Disease; and trauma, such as spinal cord injury.
Inventors
- 👤 Bernhard A. Sabel
- 👤 Andrew Freese
- 👤 William M. Saltzman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:11
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2072; A61K9/0012; A61K9/0085; A61K9/2004; A61K9/2022; A61K9/2027
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
114 words
A method for treating disorders of the nervous system comprising: Selecting a compound which stimulates or replaces a specific function of components or the nervous system selected from the group consisting of L-dopa, dopamine, carbidopa, choline, acetyl choline, cholinergic neuronotropic agents, gangliosides, nerve growth enhancing agents, antipsychotropic agents, antidepressants, excitatory amino acid antagonist or agonist, antiepileptic medications enzymes and combinations thereof; selecting a biocompatible polymer; encapsulating said compound within said polymer to form a polymeric device having at least one opening at the surface, wherein said compound is linearly released from said polymeric device over a sustained period of time greater than three months at a predetermined level and rate to the nervous system.
Claim 2
Independent Claim
114 words
A method for treating disorders of the nervous system comprising: Selecting a compound which stimulates or replaces a specific function of components or the nervous system selected from the group consisting of L-dopa, dopamine, carbidopa, choline, acetyl choline, cholinergic neuronotropic agents, gangliosides, nerve growth enhancing agents, antipsychotropic agents, antidepressants, excitatory amino acid antagonist or agonist, antiepileptic medications enzymes and combinations thereof; selecting a biocompatible polymer; encapsulating said compound within said polymer to form a polymeric device having at least one opening at the surface, wherein said compound is linearly released from said polymeric device over a sustained period of time greater than three months at a predetermined level and rate to the nervous system.
Claim 3
Dependent Claim
30 words
The method of claim 1 further comprising implanting said polymeric device at a location within a patient wherein the release of said compound produces a desired effect on the patient.
Claim 4
Dependent Claim
27 words
The method of claim 1 wherein said polymer is selected from the group of bioerodible polymers consisting of polyanhydrides, polylactic acid, polyglycolic acid, polyorthoesters, and combinations thereof.
Claim 5
Dependent Claim
27 words
The method of claim 1 wherein said polymer is selected from the group of polymers consisting of ethylene vinyl acetate, polyurethanes, polystyrenes, polyamide, polyacrylamide, and combinations thereof.
Claim 6
Dependent Claim
19 words
The method of claim 1 wherein the polymer is selected to control the rate of release of said compound.
Claim 7
Dependent Claim
33 words
The method of claim 1 further comprising forming said polymer around said compound in a thickness and with a specific area calculated to provide sustained, linear release over a predetermined period of time.
Claim 8
Dependent Claim
48 words
The method of claim 1 wherein said compound is selected from the group of compounds consisting of L-dopa, dopamine, carbidopa, choline, acetylcholine, cholinergic neuronotrophic agents, gangliosides, nerve growth enhancing agents, antipsychotic agents, antidepressants, excitatory amino acid antagonists and agonists, antiepileptic medications, antibiotics, enzymes, anti-viral agents, and combinations thereof.
Claim 9
Dependent Claim
23 words
The method of claim 1 for treating Parkinson's disease wherein said compound is selected from the group consisting of L-dopa, carbidopa, and dopamine.
Claim 10
Dependent Claim
15 words
The method of claim 1 for treating nervous system injury wherein said compound is gangliosides.
Claim 11
Dependent Claim
20 words
The method of claim 1 for treating Alzheimer's Disease wherein said compound is a cholinergic agonist, antagonist or neuronotrophic agent.
Claim 12
Dependent Claim
14 words
The method of claim 1 for treating multiple sclerosis wherein said compound is beta-interferon.
Claim 13
Dependent Claim
19 words
The method of claim 1 for treating Huntington's Disease wherein said compound is an antagonist of excitatory amino acids.
Claim 14
Dependent Claim
14 words
The method of claim 1 wherein said encapsulated compound is implanted within the brain.
Claim 15
Dependent Claim
17 words
The method of claim 1 wherein said encapsulated compound is implanted immediately adjacent the peripheral nervous system.
Claim 16
Dependent Claim
33 words
The method of claim 1 further comprising forming a second, impermeable polymer surface on said polymeric device and creating discrete openings in said second surface to control the rate and level of release.
Claim 17
Dependent Claim
144 words
A composition for treating disorders of the nervous system comprising: a compound which stimulates or replaces a specific function of components of the nervous system selected from the group consisting of L-dopa, dopamine, carbidopa, choline, acetylcholine, cholinergic neuronotrophic agents, gangliosides, nerve growth enhancing agents, antipsychotropic agents, antidepressants, excitatory amino acid antagonists or agonists, antiepileptic medications, enzymes, and combinations thereof; a biocompatible polymer matrix; wherein said compound is encapsulated within said polymeric matrix, said polymeric device having at least one opening at the surface allowing access of liquid at the treatment site to the compound, wherein the compound is linearly released over a sustained period of time in excess of three months in a predetermined amount and rate through the opening as the compound dissolves into the liquid entering the device through the opening. and areas where the compound has dissolved within the polymeric device.
Claim 18
Dependent Claim
144 words
A composition for treating disorders of the nervous system comprising: a compound which stimulates or replaces a specific function of components of the nervous system selected from the group consisting of L-dopa, dopamine, carbidopa, choline, acetylcholine, cholinergic neuronotrophic agents, gangliosides, nerve growth enhancing agents, antipsychotropic agents, antidepressants, excitatory amino acid antagonists or agonists, antiepileptic medications, enzymes, and combinations thereof; a biocompatible polymer matrix; wherein said compound is encapsulated within said polymeric matrix, said polymeric device having at least one opening at the surface allowing access of liquid at the treatment site to the compound, wherein the compound is linearly released over a sustained period of time in excess of three months in a predetermined amount and rate through the opening as the compound dissolves into the liquid entering the device through the opening. and areas where the compound has dissolved within the polymeric device.
Claim 19
Dependent Claim
30 words
The composition of claim 16 further comprising a second impermeable biocompatible polymer surface, said second surface having discrete openings to control the rate and level of release of said compound.
Claim 20
Dependent Claim
27 words
The composition of claim 16 wherein said polymer is selected from the group of bioerodible polymers consisting of polyanhydrides, polylactic acid, polyglycolic acid, polyorthoesters, and combinations thereof.
Claim 21
Dependent Claim
27 words
The composition of claim 16 wherein said polymer is selected from the group of polymers consisting of ethylene vinyl acetate, polyurethanes, polystyrenes, polyamide, polyacrylamide, and combinations thereof.
Claim 22
Dependent Claim
17 words
The composition of claim 16 wherein the polymer composition affects the rate of release of said compound.
Claim 23
Dependent Claim
33 words
The composition of claim 16 wherein said polymer is formed around said compound in a thickness and with a specific area calculated to provide sustained, linear release over a predetermined period of time.
Claim 24
Dependent Claim
21 words
The composition of claim 16 further comprising a compound selected from the group consisting of antibiotics, anti-viral agents and combinations thereof.
References Cited (Backward Citations)
US3880991A
Cited
US3625214A
Cited
US3832252A
Cited
US4069307A
Cited
US3948254A
Cited
US4177256A
Cited
US4351337A
Cited
US3976071A
Cited
US3965255A
Cited
US4391797A
Cited
US4217898A
Cited
US4263273A
Cited
US4278087A
Cited
US4675189A
Cited
EP0168862A2
Cited
GB2167662A
Cited
EP0226061A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-11-27 | 1993-05-29 | 1993-11-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-11-27 | 1997-05-29 | 1997-11-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-11-27 | 2001-05-29 | 2001-11-28 | $7700.00 | Window Closed / Lapsed |